Senzime AB (publ)
STO:SEZI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (15.5), the stock would be worth kr-13.12 (371% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.7 | kr4.84 |
0%
|
| Industry Average | 15.5 | kr-13.12 |
-371%
|
| Country Average | 17.8 | kr-15.1 |
-412%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Senzime AB (publ)
STO:SEZI
|
760.1m SEK | -5.7 | -5.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 55.9 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 18.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 23.9 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 18.8 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 25.3 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 15.1 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 27.2 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 33.3 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 16.6 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.8 | 21.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 14 |
| Median | 17.8 |
| 70th Percentile | 23.3 |
| Max | 4 325.3 |
Other Multiples
Senzime AB (publ)
Glance View
Senzime AB engages in the development of enzyme-based biosensor technology for medical and biochemical processes and industries. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2008-06-18. The firm focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
